ImmunityBio (IBRX) Short term Debt (2015 - 2021)
ImmunityBio (IBRX) posted quarterly Short term Debt of $8.7 million for Q3 2021, up 541.37% year-over-year from $1.4 million in Q3 2020, and down 47.96% quarter-over-quarter from $16.7 million in Q2 2021.
ImmunityBio (IBRX) Short term Debt (2015 - 2021) Analysis & Trends
ImmunityBio (IBRX) has reported Short term Debt for 7 consecutive years, with $8.7 million the latest figure, recorded in Q3 2021.
- In Q3 2021, Short term Debt rose 541.37% year-over-year to $8.7 million; the TTM figure through Sep 2021 stood at $8.7 million (up 541.37% YoY), while the FY2020 annual figure was $14.8 million, up 2953.09% from the prior year.
- Short term Debt retreated to $8.7 million in Q3 2021 per IBRX's latest filing, from $16.7 million in the prior quarter.
- Across five years, Short term Debt topped out at $17.8 million in Q1 2021 and bottomed at $486000.0 in Q4 2019.
- Historically, Short term Debt has averaged $4.5 million across 5 years, with a median of $2.1 million in 2017.
- Annual changes were most pronounced in 2019 — Short term Debt tumbled 71.34% — and 2020, when it soared 2953.09%.
- ImmunityBio's Short term Debt stood at $2.4 million in 2017, then retreated by 28.23% to $1.7 million in 2018, then sank by 71.34% to $486000.0 in 2019, then jumped by 2953.09% to $14.8 million in 2020, then tumbled by 41.39% to $8.7 million in 2021.
- Business Quant data shows IBRX's Short term Debt at $8.7 million in Q3 2021, $16.7 million in Q2 2021, and $17.8 million in Q1 2021.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | ImmunityBio | 7.97 Bn | 7.62 Bn | 50.94 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2021 | 8.70 Mn |
| Jun 30, 2021 | 16.71 Mn |
| Mar 31, 2021 | 17.82 Mn |
| Dec 31, 2020 | 14.84 Mn |
| Sep 30, 2020 | 1.36 Mn |
| Jun 30, 2020 | 2.23 Mn |
| Mar 31, 2020 | 853,000.00 |
| Dec 31, 2019 | 486,000.00 |
| Sep 30, 2019 | 868,000.00 |
| Jun 30, 2019 | 957,000.00 |
| Mar 31, 2019 | 1.53 Mn |
| Dec 31, 2018 | 1.70 Mn |
| Sep 30, 2018 | 2.18 Mn |
| Jun 30, 2018 | 1.81 Mn |
| Mar 31, 2018 | 2.46 Mn |
| Dec 31, 2017 | 2.36 Mn |
| Sep 30, 2017 | 1.99 Mn |
| Mar 31, 2017 | 2.12 Mn |
| Dec 31, 2016 | 1.75 Mn |
| Sep 30, 2016 | 1.85 Mn |